Domov › Poklici › Regulatory Affairs Managers › Gaithersburg, MD
Regulatory Affairs Managers v Gaithersburg, MD: plače H-1B
20 vlog za delovne pogoje za ta poklic z delovnim mestom v Gaithersburg, MD. Medianna osnovna plača $164.800; srednja polovica $143.750–$184.732.
Po plačilnem razredu
| Raven plače | Mediana plače |
|---|---|
| Stopnja I (začetna) | $128.750 |
| Stopnja II (kvalificirana) | $138.682 |
| Stopnja III (izkušena) | $173.802 |
| Stopnja IV (polno usposobljena) | $195.000 |
Department of Labor določi štiri stopnje prevladujočih plač za vsak poklic in območje, od Stopnje I (začetna) do Stopnje IV (popolna usposobljenost). Delodajalec izbere stopnjo, ki ustreza zahtevam delovnega mesta.
Delodajalci
| Delodajalec | LCA | Mediana plače |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $178.104 |
| Novavax, Inc. | 7 | $160.000 |
| Alexion Pharmaceuticals, Inc. | 2 | $208.284 |
| Emergent Product Development Gaithersburg Inc. | 1 | $140.000 |
| Salubris Biotherapeutics Inc. | 1 | $128.750 |
| Horizon Therapeutics USA, Inc. | 1 | $167.200 |
Nazivi delovnih mest
- Associate Director,Safety Surveillance Global Vaccine Safety4
- Associate Regulatory Affairs Director3
- Senior Manager, QPPV Office, Global Vaccine Safety2
- Manager, Regulatory Affairs CMC1
- Director, Quality Science and Processes1
- Manager, Regulatory Affairs1
- Manager Corporate Strategy and Clinical Development1
- Sr. Manager, CMC Regulatory Affairs (Rare Disease)1
- Associate Director, Regulatory Science & Execution1
- Director, Labeling1
- Associate Regulatory Affair Director1
- Associate Director, Patient Safety Scientist1
- Regulatory Affairs Portfolio Director1
- Global Regulatory Affairs Director1
Sponzorji H-1B v Gaithersburg, MD →
Plače so spodnja meja ponujene plače pri vsaki vlogi, pretvorjene v letni znesek; statistika uporablja samo potrjene vloge za polni delovni čas. LCA ni odobritev vizuma, ena LCA pa lahko pokriva več delovnih mest. Vir: U.S. Department of Labor, OFLC LCA Disclosure Data, davčna leta 2023–2026 (najnovejša odločitev 30. jun. 2026).